APA (7th ed.) Citation

Riess, J., Spicer, J., Seiwert, T., Villaflor, V., Rubio Perez, J., Shaw, P., . . . Garrido Lopez, P. (2024). 1022P A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: Completed cohort for first-line (1L) treatment of advanced squamous cell carcinoma of the head and neck (SCCHN). Annals of Oncology, 35, S691. https://doi.org/10.1016/j.annonc.2024.08.1081

Chicago Style (17th ed.) Citation

Riess, J.W, et al. "1022P A Phase II Trial of the IO102-IO103 Vaccine Plus Pembrolizumab: Completed Cohort for First-line (1L) Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)." Annals of Oncology 35 (2024): S691. https://doi.org/10.1016/j.annonc.2024.08.1081.

MLA (9th ed.) Citation

Riess, J.W, et al. "1022P A Phase II Trial of the IO102-IO103 Vaccine Plus Pembrolizumab: Completed Cohort for First-line (1L) Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)." Annals of Oncology, vol. 35, 2024, p. S691, https://doi.org/10.1016/j.annonc.2024.08.1081.